Biotech by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
CG Oncology leads the 19 biotech ranked by P/S ratio, at 1767, ahead of CRISPR Therapeutics (1156) and Kymera Therapeutics (263). Figures as of 18 Nov 2026, 16:31 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 19
- First
- CG Oncology1767
- Median
- 14.3
- Combined market value
- PLN 3.39T
- Countries
- 5
- Not ranked
- 5no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | P/S ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | CG OncologyCGON · Health Care | 1767 | PLN 28.7B | PLN 321.81 | 1.25% up | 85% up | ||
| 2 | CRISPR TherapeuticsCRSP · Health Care | 1156 | PLN 16.3B | PLN 168.37 | 4.16% up | 21% down | ||
| 3 | Kymera TherapeuticsKYMR · Health Care | 263 | PLN 41.6B | PLN 487.12 | 0.44% down | 87% up | ||
| 4 | ImmunityBioIBRX · Health Care | 62.1 | PLN 28.3B | PLN 26.61 | 5.59% up | 193% up | ||
| 5 | ModernaMRNA · Health Care | 41.9 | PLN 328.3B | PLN 811.41 | 2.55% down | 755% up | ||
| 6 | Krystal BiotechKRYS · Health Care | 23.6 | PLN 37B | PLN 1,248.35 | 3.86% up | 46% up | ||
| 7 | Twist BioscienceTWST · Health Care | 21.0 | PLN 31.8B | PLN 466.03 | 3.35% up | 340% up | ||
| 8 | Adaptive BiotechnologiesADPT · Health Care | 16.5 | PLN 18.4B | PLN 113.78 | 0.81% down | 88% up | ||
| 9 | RepligenRGEN · Health Care | 14.8 | PLN 44.1B | PLN 689.56 | 5.60% up | 5% up | ||
| 10 | argenxARGX · Health Care | 14.3 | PLN 238.8B | PLN 3,797.61 | 0.45% down | 4% up | ||
| 11 | Bio-TechneTECH · Health Care | 9.4 | PLN 46B | PLN 292.82 | 0.14% up | 26% up | ||
| 12 | Halozyme TherapeuticsHALO · Health Care | 7.9 | PLN 44.6B | PLN 390.96 | 1.18% up | 37% up | ||
| 13 | ExelixisEXEL · Health Care | 7.3 | PLN 67.9B | PLN 278.45 | 0.96% up | 63% up | ||
| 14 | Gilead SciencesGILD · Health Care | 7.1 | PLN 846.2B | PLN 682.21 | 0.48% down | 33% up | ||
| 15 | AmgenAMGN · Health Care | 6.6 | PLN 973.3B | PLN 1,799.41 | 2.40% down | 34% up | ||
| 16 | BioNTechBNTX · Health Care | 6.5 | PLN 84B | PLN 338.62 | 0.89% down | 16% down | ||
| 17 | Neurocrine BiosciencesNBIX · Health Care | 5.8 | PLN 66.4B | PLN 655.62 | 1.86% down | 20% up | ||
| 18 | QiagenQGEN · Health Care | 4.9 | PLN 41.2B | PLN 199.48 | 0.41% down | 12% up | ||
| 19 | BiogenBIIB · Health Care | 3.7 | PLN 148.7B | PLN 1,006.26 | 0.34% down | 49% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0262 PLN). 5 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which biotech rank first by P/S ratio?
CG Oncology (1767), CRISPR Therapeutics (1156) and Kymera Therapeutics (263) are the top three of the 19 biotech ranked by P/S ratio as of 18 Nov 2026, 16:31 UTC.
How many biotech are in this ranking?
19 are ranked by P/S ratio. 5 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these biotech worth together?
The 19 biotech ranked by P/S ratio have a combined market value of PLN 3.39T as of 18 Nov 2026, 16:31 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by P/S ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.